Surgical decompression for Bell’s palsy

Surgical decompression for Bell’s palsy

Understanding Bell’s palsy

Bell’s palsy is a distressing condition characterised by sudden, temporary weakness or paralysis of facial muscles on one side of the face which occurs within 72 hours. The most commonly accepted cause is Herpes simplex virus. Bell’s palsy is the cause in nearly 80% of  unilateral facial nerve paralysis. Bell’s Palsy can lead to a range of symptoms, including drooping of the mouth, difficulty closing the eye, altered taste sensation, and increased sensitivity to sound. The emotional and psychological impact can be significant, as patients may feel self-conscious about their appearance and experience anxiety related to their facial mobility. Given the potential for profound effects on quality of life, prompt and effective treatment options are crucial.

Bell’s palsy on the left side
Bell’s palsy on the left side

Surgical Decompression: A proven approach

Surgical decompression is a viable treatment option for patients diagnosed with Bell’s palsy, particularly for those presenting with severe symptoms. The main reason for this is that outcomes are poor in 15%  of patients . According to the literature, decompression surgery, when performed within the first two weeks after the onset of paralysis, can lead to significant improvements in functional outcomes. Specifically, patients exhibiting a House-Brackmann grade of 6, indicated by no facial movement, combined with electroneurography (ENoG) findings showing a 90% reduction in compound action potential (CAP), may benefit most from early intervention.

Notably, the surgical approach that has shown the most promise is the middle fossa (transtemporal) approach, which decompresses the meatal foramen and surrounding areas. This specific method effectively addresses the pathological changes in the facial nerve; therefore, it is crucial to avoid the mastoid segment, as it has not demonstrated beneficial outcomes in similar cases.

The Contributions of Dr Bruce Gantz

The pioneering work of Dr Bruce Gantz from the University of Iowa has provided significant insight into the efficacy of surgical decompression for Bell’s palsy. His research indicates that patients undergoing this procedure exhibit notably improved recovery rates in terms of facial function, with reported improvements reaching as high as 91% in a specific subset when compared with the non-surgical group, in which only 42% recovered satisfactorily —a highly significant finding. This emphasises the importance of early surgical intervention, especially when patients present with severe electrophysiological findings.

Dr Bruce Gantz from Iowa
Dr Bruce Gantz from Iowa

Understanding the Mechanism of Decompression

Surgical decompression involves the release of the fibrous band at the meatal foramen, a critical watershed area supplied by the anterior inferior cerebellar artery (AICA) and the stylomastoid artery, alongside the blood supply from the superior petrosal nerve artery. The significance of this revascularisation process cannot be overstated, as it alleviates the pressure on the facial nerve, potentially restoring function. Observations during surgeries often reveal clear signs of nerve revascularisation when these structures are adequately addressed. See the underlying images.

Left meatal foramen with consriction of facial nerve (white arrow) and decompressed labyrinthine segment (black arrow).
Compression of nerve at meatal foramen (white arrow)
Decompressed nerve at meatal foramen
Decompressed nerve at meatal foramen

Prerequisites for Successful Surgery

The surgeon performing the decompression surgery must have extensive training and experience with this specialised procedure. The complexity of the surgery requires not only precision but also a comprehensive understanding of the anatomical and physiological factors associated with Bell’s palsy. Surgery should be performed within two weeks of onset in patients with House-Brackmann 6 weakness, an electroneurography (ENoG) reduction of more than 90%, and needle EMG needle confirmation of absent voluntary muscle potentials.

Management Beyond Surgery

It is important to note that surgical decompression is not considered adequate after the two-week mark following paralysis onset. Therefore, prompt action is crucial. In conjunction with surgery, the administration of corticosteroids and anti- viral therapy should be standard practice to mitigate inflammation and promote recovery. There is also a growing opinion among experts advocating for the use of antiviral agents to complement treatment, particularly given the potential viral aetiology of Bell’s palsy. I also advocate mime therapy. The addition of Vitamin B complex is not proven.

Furthermore, protecting the eye on the affected side is essential to prevent complications such as corneal abrasion, as a diminished blink reflex can lead to exposure issues.

Facial paralysis on the patient’s right side
Facial paralysis on the patient’s right side

The Orphan Nature of Bell’s palsy

Bell’s palsy is classified as an orphan disorder, which denotes its occurrence in a relatively small subset of the population. Research is limited, and major pharmaceutical companies do not invest in financial contributions towards research. As a result, awareness and understanding among the general public and healthcare providers can be limited, potentially leading to delayed diagnosis and treatment. Greater education and outreach are vital to ensure that individuals experiencing symptoms receive appropriate and expedited care.

Dr Hofmeyr’s experience

Dr Hofmeyr has performed more than 30 facial nerve decompressions through the middle fossa for conditions such as Bell’s palsy, Sclerosteosis and Recurrent facial nerve paralysis.

References

1. Gantz BJ, Rubinstein JT, Gidley P, Woodworth GG. Surgical management of Bell’s palsy. Laryngoscope. 1999 Aug;109(8):1177-88. doi: 10.1097/00005537-199908000-00001. PMID: 10443817.

2. Fisch U. Surgery for Bell’s palsy. Arch Otolaryngol. 1981 Jan;107(1):1-11. doi: 10.1001/archotol.1981.00790370003001. PMID: 7469872.

3. Cannon RB, Gurgel RK, Warren FM, Shelton C. Facial nerve outcomes after middle fossa decompression for Bell’s palsy. Otol Neurotol. 2015 Mar;36(3):513-8. doi: 10.1097/MAO.0000000000000513. PMID: 25058839.

4. Gantz BJ, Gmür A, Fisch U. Intraoperative evoked electromyography in Bell’s palsy. Am J Otolaryngol. 1982 Jul-Aug;3(4):273-8. doi: 10.1016/s0196-0709(82)80066-5. PMID: 7149140.

5. Andresen NS, Zhu V, Lee A, Sebetka W, Kimura J, Hansen MR, Gantz BJ, Sun DQ. Electrodiagnostic testing in acute facial palsy: Outcomes and comparison of methods. Laryngoscope Investig Otolaryngol. 2020 Sep 10;5(5):928-935. doi: 10.1002/lio2.458. PMID: 33134541; PMCID: PMC7585247.

6. Song Y, McHugh C, Tirino J, Hadlock T, Santos F. Middle Fossa Decompression for Recurrent Facial Palsy: Prevalence and Surgical Outcomes. Laryngoscope. 2023 May;133(5):1222-1227. doi: 10.1002/lary.30344. Epub 2022 Aug 15. PMID: 37042775.

7. Schwartz SR, Jones SL, Getchius TS, Gronseth GS. Reconciling the clinical practice guidelines on Bell’s palsy from the AAO-HNSF and the AAN. Otolaryngol Head Neck Surg. 2014 May;150(5):709-11. doi: 10.1177/0194599814529079. PMID: 24789656.

8. Zhu Y, Yang Y, Wang D, Dong M. Idiopathic recurrent facial palsy: Facial nerve decompression via middle cranial fossa approach. Am J Otolaryngol. 2016 Jan-Feb;37(1):31-3. doi: 10.1016/j.amjoto.2015.09.004. Epub 2015 Sep 10. PMID: 26700256.

9. Glasscock ME 3rd, House WF, Alford BR. Middle fossa facial nerve decompression. Ann Otol Rhinol Laryngol. 1970 Apr;79(2):234-40. doi: 10.1177/000348947007900203. PMID: 5437643.

10. Azuma T, Nakamura K, Takahashi M, Miyoshi H, Toda N, Iwasaki H, Fuchigami T, Sato G, Kitamura Y, Abe K, Takeda N. Electroneurography cannot predict when facial synkinesis develops in patients with facial palsy. J Med Invest. 2020;67(1.2):87-89. doi: 10.2152/jmi.67.87. PMID: 32378624.

11. Andresen NS, Sun DQ, Hansen MR. Facial nerve decompression. Curr Opin Otolaryngol Head Neck Surg. 2018 Oct;26(5):280-285. doi: 10.1097/MOO.0000000000000478. PMID: 30138146.